API Quick Links: http://en.hichipharm.com/
+86-152-0110-8103
yanglm@beilupharma.com
EN
EN
jp
fr
de
es
ru
pt
ar
Home
Products
Products
Contrast Media
Anti-Diabetic Drugs
Anti-Anxiety Drug
API
Intermediates
Excipients
Contrast Media
MRI Contrast Media
CT/X-Ray Contrast Media
Gadopentetate Dimeglumine Injection/API
Gadobutrol Injection/API
Gadobenate Dimeglumine Injection
Ferric Ammonium Citrate Effervescent Granules
Iohexol Injection
Iopamidol Injection
Iodixanol Injection
Gadopentetate Dimeglumine Injection/API
Gadobutrol Injection/API
Gadobenate Dimeglumine Injection
Ferric Ammonium Citrate Effervescent Granules
Iohexol Injection
Iopamidol Injection
Iodixanol Injection
Anti-Diabetic Drugs
Glimepiride Tablets
Repaglinide Tablets
Glimepiride Tablets
Repaglinide Tablets
Anti-Anxiety Drug
Traditional Chinese Medicine-Jiuweizhenxin Granules
Traditional Chinese Medicine-Jiuweizhenxin Granules
API
Iohexol
Iopamidol
Ioversol
Iopromide
Iodixanol
Gadopentetate Dimeglumine
Gadopentetate Monomeglumine
Gadobutrol
Repaglinide
Iohexol
Iopamidol
Ioversol
Iopromide
Iodixanol
Gadopentetate Dimeglumine
Gadopentetate Monomeglumine
Gadobutrol
Repaglinide
Intermediates
Iohexol Intermediate 5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Iohexol/Ioversol Intermediate 5-Amino-N, N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Ioversol Intermediate (order based) N, N'-Bis(2,3-dihydroxypropyl)-5-(glycoloylamino)-2,4,6-triiodoisophthalamide
Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid
Iopamidol Intermediate (order based) 5-Amino-2,4,6- triiodisophthaloyl acid dichloride
Diethylenetriaminepentaacetic acid (DTPA)
Iohexol Intermediate 5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Iohexol/Ioversol Intermediate 5-Amino-N, N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Ioversol Intermediate (order based) N, N'-Bis(2,3-dihydroxypropyl)-5-(glycoloylamino)-2,4,6-triiodoisophthalamide
Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid
Iopamidol Intermediate (order based) 5-Amino-2,4,6- triiodisophthaloyl acid dichloride
Diethylenetriaminepentaacetic acid (DTPA)
Excipients
Calcobutrol
Calcobutrol
Company
About Beilu Pharma
Research & Development
Qualifications
News
Corporate News
Blog Update
Contact Us
English
日本語
français
Deutsch
Español
русский
português
العربية
Search
Home
Products
Contrast Media
Anti-Diabetic Drugs
Anti-Anxiety Drug
API
Intermediates
Excipients
Specialities
Cisternography
Myelography
Ventriculography
Angiography
Sialography
Company
About Beilu Pharma
Research & Development
Qualifications
News
Corporate News
Blog Update
Contact Us
Home
Products
Contrast Media
MRI Contrast Media
CT/X-Ray Contrast Media
Anti-Diabetic Drugs
Glimepiride Tablets
Repaglinide Tablets
Anti-Anxiety Drug
Traditional Chinese Medicine-Jiuweizhenxin Granules
API
Iohexol
Iopamidol
Ioversol
Iopromide
Iodixanol
Gadopentetate Dimeglumine
Gadopentetate Monomeglumine
Gadobutrol
Repaglinide
Intermediates
Iohexol Intermediate 5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Iohexol/Ioversol Intermediate 5-Amino-N, N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Ioversol Intermediate (order based) N, N'-Bis(2,3-dihydroxypropyl)-5-(glycoloylamino)-2,4,6-triiodoisophthalamide
Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid
Iopamidol Intermediate (order based) 5-Amino-2,4,6- triiodisophthaloyl acid dichloride
Diethylenetriaminepentaacetic acid (DTPA)
Excipients
Calcobutrol
Specialities
Cisternography
Myelography
CT myelogram
MRI myelogram
Ventriculography
Angiography
CT angio head
CT angio chest
Sialography
Company
About Beilu Pharma
Research & Development
Qualifications
GMP Contrast Media
GMP Certificate
ISO 14001:2015
ISO 9001:2015
ISO 50001:2011
ISO 45001:2018
News
Corporate News
Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets
CPHI China 2024 Invitation
Congratulations: Beilu Pharma's Iodixanol Injection Passed the Consistency Evaluation for Generic Drugs
Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement
109 Million! Subsidiary Hichi Pharmaceutical Completed a New Round of Financing to Help Increase Profitability
New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation
Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!
Beilu Pharma Invested 192 Million Yuan In Cangzhou Raw Material Production Project
Beilu Pharma's Gadobutrol Injection Has Been Approved By NMPA
Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched
Beilu Pharmaceutical Intends to Establish a Wholly-owned Subsidiary in Hong Kong
Beilu was Awarded the Title of A-class enterprise for safety production
Beilu Pharmaceutical has Won the '2022 China Top 500 Corporate Philanthropy' Award!
Congratulations: Beilu Pharma's Iohexol Injection Passed the Consistency Evaluation for Generic Drugs
Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit
Big News! Beilu Pharmaceutical Acquired Hichi Pharmaceutical to Strengthen the Layout of Contrast Agent APIs
Beilu Pharmaceutical's Repaglinide Tablets Receive Generic Drug Bioequivalence Assessment
Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation
Beilu was awarded the “Top 100 Small and Medium-sized Private Enterprises in Beijing” and “Top 100 Private Enterprises in Beijing for Social Responsibility”
Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement
Beilu's Iopamidol Injection Won the Bid for China's Pharmaceutical Centralized Procurement
Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.
Beilu Pharma Established a Wholly-owned R&D Subsidiary
Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO
CPhl China 2023 Invitation
Beijing Beilu Pharmaceutical Invites You to Participate in the 2023 Beijing International LIfe and Health Industry Expo
Beilu Pharmaceutical Has Won the
Good News: Beilu Pharmaceutical's Jiuwei Zhenxin Granules Included in 18 Industry Consensus Guidelines
Foreign Journalists Visit Beilu Pharmaceutical to Learn about Beijing's Green Development
CPHI WORLDWIDE 2023
Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.
Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 20 Industry Guidelines Consensus Teaching Materials
Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 21 Industry Guidelines Consensus Teaching Materials
Beilu Pharmaceutical Plans to Acquire Tianyuan Pharmaceutical, Actively Building "Second Growth Curve"
Beilu Pharmaceutical's Gadobenate Dimeglumine Injection Passes Generic Drug Consistency Evaluation!
Beilu Pharmaceutical Officially Acquires Tianyuan Pharmaceutical, Continues to Advance the Strategic Layout of Traditional Chinese Medicine
【New Product】Beilu Pharmaceutical's Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved
【Good News】Beilu Pharmaceutical once again honored as "Beijing Advanced Unit for Daily Monitoring of Adverse Drug Reactions"
【New Product】Beilu Pharmaceutical's Gadoteric Acid Meglumine Injection and API Approved
Hichi Pharmaceutical's Iodixanol API Approved for Market
Beilu Pharmaceutical Obtains GMP Certification from ANVISA
Beilu Pharma's Contrast Media Production Line Passed EU GMP Certification.
Blog Update
Jiuwei Zhenxin Granules - Independent Innovation, Classic Inheritance
Adverse Reaction and Treatment of Contrast Medium
Notice
Introduction of Contrast Medium
Future Trend
Frequently Asked Questions about Iodine Contrast Users(1)
Frequently Asked Questions about Iodine Contrast Users (2)
Frequently Asked Questions about Iodine Contrast Users (3)
To Understand the Development of Iodinated Contrast Agents
Adverse Drug Reaction (ADR) and Treatment of Major Iodinated Contrast Agents
Knowledge About Non Ionic Contrast Medium
Introduction of Intravenous Contrast Media
Uses of Ferric Ammonium Citrate
The Enhanced CT and Ordinary CT: Not Only to See More Clearly
Anti Anxiety Drugs More Effective Than Blood Pressure Medication for Mood-induced Hypertension
What is the Contrast Material? How Does It Work?
Contact Us
Contact Us
Home
News
Blog Update
Future Trend
Future Trend
News
Corporate News
Blog Update
Contrast Media
MRI Contrast Media
Gadopentetate Dimeglumine Injection/API
Gadobutrol Injection/API
Gadobenate Dimeglumine Injection
Ferric Ammonium Citrate Effervescent Granules
CT/X-Ray Contrast Media
Iohexol Injection
Iopamidol Injection
Iodixanol Injection
Anti-Diabetic Drugs
Glimepiride Tablets
Repaglinide Tablets
Anti-Anxiety Drug
Traditional Chinese Medicine-Jiuweizhenxin Granules
API
Iohexol
Iopamidol
Ioversol
Iopromide
Iodixanol
Gadopentetate Dimeglumine
Gadopentetate Monomeglumine
Gadobutrol
Repaglinide
Intermediates
Iohexol Intermediate 5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Iohexol/Ioversol Intermediate 5-Amino-N, N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Ioversol Intermediate (order based) N, N'-Bis(2,3-dihydroxypropyl)-5-(glycoloylamino)-2,4,6-triiodoisophthalamide
Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid
Iopamidol Intermediate (order based) 5-Amino-2,4,6- triiodisophthaloyl acid dichloride
Diethylenetriaminepentaacetic acid (DTPA)
Excipients
Calcobutrol
Call us on:
+86-152-0110-8103
Email Us:
yanglm@beilupharma.com
No.3 Shuiyuan West Road, Miyun District, Beijing, China
Products
Contrast Media
Anti-Diabetic Drugs
Anti-Anxiety Drug
API
Intermediates
Excipients
Specialities
Cisternography
Myelography
Ventriculography
Angiography
Sialography
Company
About Beilu Pharma
Research & Development
Qualifications
News
Corporate News
Blog Update
Sitemap
|
Privacy Policy
Copyright ©
Beijing Beilu Pharmaceutical Co., Ltd.
All Rights Reserved.
+86-152-0110-8103
Your browser does not support VBScript!